Dexcom’s shares rose 3.0% after earnings. Revenue grew 11% year over year, with 14% growth in the U.S., while the company highlighted continued U.S. share gains and progress toward broader CGM access.
- Third-quarter revenue increased 11% year over year on both a reported and organic basis.
- U.S. revenue grew 14%; Dexcom said it gained share, with the largest increase among customers with type 2 diabetes, including those not on insulin.
- Dexcom expects a CMS decision on type 2 non-insulin coverage this year. Its CONNECT trial found a 0.9% A1c difference between the CGM and control groups over six months.
- G7 15 Day adoption built during the quarter; Dexcom remains on track to convert nearly 50% of its U.S. customer base by year-end.
- Dexcom reported a 4- to 5-point improvement in 15 Day survivability as the updated adhesive rolls out.
Community Discussion